Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.41 |
| ▸ | TUBB | P07437 | 2/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664975 | 0.88 | PDE4D (0.36) | HDAC1HDAC6TUBB4ATUBBTUBA3C | |
| SCHEMBL15665181 | 0.88 | HDAC1 (0.36) | MAPTHDAC1HDAC6TUBB4ATUBB | |
| SCHEMBL17085753 | 0.88 | HDAC1 (0.47) | ALDH1A1HDAC1HDAC6TUBB4ATUBB | |
| SCHEMBL28807093 | 0.88 | HDAC1 (0.48) | ALDH1A1MEN1MAPTKMT2AHDAC1 | |
| SCHEMBL15664909 | 0.86 | TUBB4A (0.43) | ALDH1A1HDAC1HDAC6TUBB4ATUBB | |
| SCHEMBL15664667 | 0.86 | TUBB4A (0.43) | ALDH1A1HDAC1HDAC6TUBB4ATUBB | |
| SCHEMBL14973903 | 0.86 | TUBB4A (0.51) | HDAC1HDAC6TUBB4ATUBBTUBA3C | |
| SCHEMBL15664452 | 0.86 | HDAC1 (0.45) | ALDH1A1HDAC1HDAC6TUBB4ATUBB | |
| SCHEMBL15664906 | 0.86 | HDAC1 (0.48) | ALDH1A1HDAC1HDAC6TUBB4ATUBB | |
| Hydrochloric Acid SCHEMBL14974403 | 0.85 | TUBB4A (0.50) | HDAC1HDAC6TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | claimed |
| CN-102863388-B | Tumor targeted drug Combretastatin A4 derivatives | NANJING SANHOME PHARMACEUTICAL CO LTD | 2015-04-29 | — | — | CN | claimed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | claimed |
| CN-102863388-A | Tumor targeted drug Combretastatin A4 derivatives | NANJING SANHOME PHARMACEUTICAL CO LTD | 2013-01-09 | — | — | CN | claimed |
| CN-105753787-B | Tumor-targeting drug Combretastatin A4 derivatives | 南京圣和药业股份有限公司 | 2018-05-15 | — | — | CN | disclosed |
| EP-2730565-B1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2017-04-26 | — | — | EP | disclosed |
| CN-103889964-B | Tumor targeting drug Combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO.,LTD. (CN) | 2016-03-02 | — | — | CN | disclosed |
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| CN-102863388-B | Tumor targeted drug Combretastatin A4 derivatives | NANJING SANHOME PHARMACEUTICAL CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-103889964-A | Tumor targeting drug Combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO LTD | 2014-06-25 | — | — | CN | disclosed |
| EP-2730565-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| CN-102863388-A | Tumor targeted drug Combretastatin A4 derivatives | NANJING SANHOME PHARMACEUTICAL CO LTD | 2013-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | TUBA4A, TUBGCP4, TUBB4A | ALDH1A1 3038/4885MEN1 2684/4885MAPT 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.